Neovacs S.A.
ALNEV.PA · PAR
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | 0.02 | 0.20 | 0.00 |
| FCF Yield | -0.38% | -1.52% | 0.38% | -0.41% |
| EV / EBITDA | 9.89 | -6.32 | -71.00 | -255.45 |
| Quality | ||||
| ROIC | -12.71% | -9.10% | -5.78% | -7.39% |
| Gross Margin | -7,354.26% | -1,244.57% | -729.30% | -3,527.14% |
| Cash Conversion Ratio | 0.34 | 0.09 | -0.33 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 78.50% | 238.17% | 226.01% | 9.39% |
| Free Cash Flow Growth | 77.65% | -327.25% | 138.48% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -0.01 | 0.05 | 0.07 |
| Interest Coverage | -0.15 | 0.00 | 0.00 | -3.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,059.51 | 108.37 | 530.44 | 1,435.06 |